Clinical trial
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory…
NCT00372905 · Northwestern University, Other · Terminated
Key facts
| NCT number | NCT00372905 |
|---|---|
| Title | Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma |
| Official title | A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE®) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients With Relapsed or Refractory Follicular Lymphoma and Transformed Non-Hodgkin's Lymphoma |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Robert H. Lurie Cancer Center |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab, bortezomib, Ibritumomab tiuxetan |
| Enrollment | 18 |
| Start date | Jul 24, 2007 |
| Primary completion | Jun 22, 2010 |
| Completion | Jul 8, 2013 |
| First posted | Sep 7, 2006 |
| Last update posted | Sep 4, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: